Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Sponsor: Vor Biopharma
Summary
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2026-02-26
Completion Date
2029-01
Last Updated
2026-04-02
Healthy Volunteers
No
Conditions
Interventions
Telitacicept
Subcutaneous injection
Placebo
Subcutaneous injection
Locations (5)
Chicago Clinical Research Institute Inc
Chicago, Illinois, United States
Accurate Clinical Research, Inc.
Lake Charles, Louisiana, United States
Novel Research LLC
Bellaire, Texas, United States
Accurate Clinical Research, Inc.
Houston, Texas, United States
Velocity Clinical Research, Waco
Waco, Texas, United States